Each month, STAT Plus aims to bring our readers market-moving analysis of the biotech, pharma, and life sciences industries. Our team of veteran reporters — from Sharon Begley to Matthew Herper — help cut through the noise to bring you the most impactful headlines, and analysis of the people, policies, and scientific breakthroughs making waves in the industry.
martes, 5 de febrero de 2019
9 big takeaways from the $74 billion Bristol-Celgene deal - STAT
9 big takeaways from the $74 billion Bristol-Celgene deal - STAT
![STAT](https://blogger.googleusercontent.com/img/proxy/AVvXsEiBk2qcvyKPM0lrJDp4iY3EG2nNuprzsrIHPqN52oWyyXpxPdIdGtI3FYjTjpvhVMC7nOO0Wfr7oOcYxoD0lN0ciLWlPFnpNpvYuCdSRubeZNA7GTy53NPsE1jS-02Aa6jd9iCyEu_asokhQ31XhI4h4Y2FJ8wFgyRcNDooJV139_eki6IVvibGknFn4Y8cLwEeJVGlemCCI9d3BM92ijpTsu1ZEI5giA=s0-d-e1-ft)
Each month, STAT Plus aims to bring our readers market-moving analysis of the biotech, pharma, and life sciences industries. Our team of veteran reporters — from Sharon Begley to Matthew Herper — help cut through the noise to bring you the most impactful headlines, and analysis of the people, policies, and scientific breakthroughs making waves in the industry.
Each month, STAT Plus aims to bring our readers market-moving analysis of the biotech, pharma, and life sciences industries. Our team of veteran reporters — from Sharon Begley to Matthew Herper — help cut through the noise to bring you the most impactful headlines, and analysis of the people, policies, and scientific breakthroughs making waves in the industry.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario